Karl has said publicly a few times that he sees optogenetics as a tool for basic scientific discovery, that then inform treatment of human patients, ie where to use transcranial magnetic stimulation. Any method that requires genetic manipulation in humans will be tricky. PNS seems likely to be the first application in humans, although there are also clinical trials going in the retina, not sure how they’ve progressed though.